Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 8:00 AM ESTÂ Net product revenue of $42.1M in 4Q and $50.7M for the year
  New England Journal of Medicine publication of the use of B-VEC eyedrop formulation
  Reached alignment with FDA to enable approval of B-VEC eyedrop formulation for the treatment of lesions in the eye of DEB patients
  First patient dosed in Phase 1 KB408 trial for the treatment of AATD; five active clinical trials in 2024
  Strong balance sheet, closing the year with $594.1M in cash and investments
